4/30/2013

With strong domestic manufacturers, high-quality production standards and an attractive clinical-trial environment, Argentina's pharmaceutical industry should grow rapidly from $5.6 billion in 2012 to an estimated $15 billion by 2020, according to the research firm GlobalData. Domestic manufacturers such as Roemmers and Bago account for half of the nation's drug market, although multinationals such as Abbott, Bayer, GlaxoSmithKline, Novartis and Roche are active as well. Argentina faces challenges from large-scale production facilities in India and China, GlobalData said, and has not yet proven able to innovate and develop New Chemical Entities.

Full Story:
PharmaTimes (U.K.)

Related Summaries